In this video, Robert Gabbay, MD, PhD, talks about the overall cost implications to diabetes management through behavioral change.
In this video, Robert Gabbay, MD, PhD, speaks about the large toll the cost of diabetes management takes on society, including long-term complications, such as amputations, kidney failure, heart disease, and blindness. Many of these complications can be prevented by effective glucose, cholesterol, and blood pressure control. In addition, effective patient behaviors, such as medication adherence and weight loss/exercise, can help improve outcomes.
He also addresses how economic incentives, such as value-based insurance design, can help promote effective patient behaviors to improve outcomes. Improving outcomes and preventing long-term complications, says Dr. Gabbay, can have a tremendous impact on lowering costs.
This video was taken on June 8, 2012, at the American Diabetes Association's 72nd Scientific Session in Philadelphia, PA.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More